Trevena Pfizer Agreement

For this reason, in light of the mutual agreements, conditions and agreements set out in the agreements, and other good and valuable considerations that are recognized for receipt and sufficiency, Pfizer agrees to fully support the technical transfer plan and implement the plan as quickly as possible; Pfizer and Trevena want to amend the agreement to reflect their mutual agreement, as provided for by this second amendment. (7) This Second Amendment can be implemented in two or more counter-parts, each being considered original and forming a common agreement together. June 2 (Reuters) - Trevena Inc :TREVENA ANNOUNCES COLLABORATION WITH IMPERIAL COLLEGE LONDON TO EVALUATE TRV027 IN COVID-19 PATIENTS. TREVENA INC - IMPERIAL COLLEGE LONDON WILL SPONSOR AND FUNDING THIS STUDY TO EVALUATE TRV027 IN COVID-19 PATIENTS. . On December 4, 2019, Trevena, Inc. (the "company") and Pfizer CenterOne Group of Pfizer Inc. ("Pfizer") made an amendment (December 2, 2019) (the "change") to the development and supply contract of December 15, 2016 (the "agreement"). In accordance with the amendment, the company and Pfizer agreed: (i) to specify, among other things, that the first "year of negotiation" begins after the month in which the company concludes its first commercial sale in good faith of a product manufactured by Pfizer pursuant to the agreement and (ii) to amend termination rights so that each party can terminate the contract if the U.S. Food and Drug Administration or any other regulatory authority does not grant administrative authorization for the product covered by the agreement by December 31, 2021. 6. In the event of a conflict between the provisions of this 2nd Amendment and the provisions of the agreement, the provisions of this 2nd Amendment are monitored.

The terms of this 2nd Amendment are the control of all the conditions of each order, sale confirmation, invoice or any other such document issued by both parties. Pfizer and Trevena are contracting parties to this Development and Supply Agreement ("the Agreement") of December 15, 2016 regarding the development, manufacture and supply of the Von Trevena von Trevena pharmaceutical link by Trevena ("product") by Pfizer. In order to reduce the risk of sourcing the product in accordance with Trevena`s business plan, the parties found that it was in their mutual interest to implement in their entirety a formal technical transfer plan to qualify the Pfizer Rocky Mount facility as a product production site. Nevertheless, the advisory committee for this drug AcelRx voted and experts warned that the term "opioid epidemic" is the most characteristic of the "opioid abuse epidemic"." Many patients, including those with cancer or other diseases that cause severe chronic pain, still need these drugs to maintain a decent quality of life.

Comments are closed.